Aquestive Therapeutics, Inc.
Lead Plaintiff Deadline: 04/30/2021
SUMMARY OF CASE:
A securities class action has been filed against Aquestive Therapeutics, Inc. (AQST) on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Aquestive securities between December 2, 2019 through September 25, 2020. This case has been filed in the USDC – NY.
The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) data included in the Libervant NDA submission showed a lower drug exposure level than desired for certain weight groups; (ii) the foregoing significantly decreased the Libervant NDA’s approval prospects; (iii) as a result, it was foreseeable that the FDA would not approve the Libervant NDA in its current form; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.